A Phase 1, Randomized, Open-Label Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous Minocin (Minocylcine) for Injection

NCT03291158 Phase 1 WITHDRAWN

This is a phase 1, safety and PK Open-Label trial evaluating the plasma, epithelial lining fluid, and alveolar macrophage concentrations of intravenous Minocin® (Minocycline) for injection in healthy adult subjects.

Details

Lead sponsor	Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Phase	Phase 1
Status	WITHDRAWN
Start date	2018-04
Completion	2018-12

Conditions

• Normal Healthy Volunteers

Interventions

• Minocycline

Primary outcomes

• Analyze plasma, ELF and Alveolar Macrophage concentrations of minocycline — 16 weeks
  Determine plasma ELF and Alveolar Macrophage concentrations of minocycline when administered to healthy adult subjects.

Countries

Austria